Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Globe Newswire•31/08/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.